

IN THE CLAIMS:

All of the pending claims 1 through 26 are presented below. Claims 20, 23, 25 and 26 are amended herein. This listing of claims will replace all prior versions and listings in the application. Please enter these claims as amended.

Listing of Claims:

1. (Original) A skin care or topical pharmaceutical composition comprising at least one inhibitor capable of inhibiting proteolytic activity of a protease and a cosmetically or pharmaceutically acceptable vehicle, and wherein the inhibitor is derived from potato.

2. (Original) The skin care or topical pharmaceutical composition of claim 1, wherein said cosmetically or pharmaceutically acceptable vehicle is selected from the group consisting of aerosol spray, cream, dispersion, emulsion, foam, gel, lotion, mousse, ointment, pomade, powder, pump spray, solid, aqueous solution, hydro-alcoholic solution and stick.

3. (Original) The skin care or topical pharmaceutical composition of claim 1, comprising from 1 to 20 wt.% of the inhibitor, based on the total weight of the composition.

4. (Original) The skin care or topical pharmaceutical composition of claim 1, having a pH in the range of about 4.8 to about 5.5.

5. (Original) The skin care or topical pharmaceutical composition of claim 1, further comprising cosmetic adjuncts, pharmaceutical adjuvants or supplements.

6. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of an aqueous liquid or hydrogel.

7. (Previously presented) The skin care or topical pharmaceutical composition of claim 1 comprised in a bandage, diaper, patch, towelette or wipe.

8. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a lotion that can be absorbed into a bandage, diaper, patch, towelette or wet wipe base sheet.

9. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a hydrogel comprising:

1 to 10 wt.% of a protease inhibitor from potato;
10-20 wt.% of one or more emollients;
1-5 wt.% of one or more thickeners;
0.1-0.5 wt.% of one or more preservatives; and
water to balance.

10. (Previously presented) The skin care or topical pharmaceutical composition of claim 1 in the form of an aqueous liquid comprising:

1 to 10 wt.% of a protease inhibitor from potato;
1-20 wt.% of one or more emollients;
0.5-3 wt.% of one or more thickeners;
0.1-0.5 wt.% of one or more preservatives; and
water to balance.

11. (Previously presented) The skin care or topical pharmaceutical composition of claim 1 in the form of a rinsing fluid comprising:

1 to 10 wt.% of a protease inhibitor from potato;
0.8-1.0 wt.% of one or more buffers;
0.1-0.5 wt.% of one or more thickeners; and
water to balance.

12. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a Lanette cream having a water content of more than 50%.

13. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a “leave-on” product.

14. (Original) An article for topical administration of a skin care or topical pharmaceutical composition comprising, said article comprising:
the skin care or topical pharmaceutical composition of claim 1.

15. (Previously presented) The article of claim 14, wherein the article is selected from the group consisting of a bandage, diaper, patch, towelette and wipe.

16. (Original) The article of claim 14, wherein the article is of the type having an absorbent portion, said absorbent portion comprising the skin care or topical pharmaceutical composition of claim 1.

17. (Original) The article of claim 16, wherein the article is a cloth or disposable diaper.

18. (Original) The article of claim 14, wherein the article is a wet wipe.

19. (Previously presented) The article of claim 18, wherein the wet wipe is packed in a pop-up dispenser.

20. (Currently amended) A method of treating or preventing perineal, perianal or peristomal inflammation caused by proteolytic activity of feces in a subject, comprising:
administering, topically, ~~an inhibitor~~ the inhibitor of proteolytic activity ~~derived from a potato~~ of claim 1 to the perineal, perianal or peristomal area of the subject, in unit dosage form containing about 0.1 to about 50 g of said inhibitor of proteolytic activity per day.

21. (Original) The method according to claim 20, wherein the inhibitor of proteolytic activity is administered as an ointment, cream, gel, spray, rinsing fluid or powder.

22. (Previously presented) The method according to claim 20, wherein a wipe is used to topically administer the inhibitor of proteolytic activity to said subject.

23. (Currently amended) A diagnostic method for studying the effect of ~~an inhibitor~~ the inhibitor of proteolytic activity of claim 1 on inflammatory action of feces, the diagnostic method comprising:

sterilizing feces;

adding at least one proteolytic enzyme to said sterilized feces;

placing a sample of said feces with proteolytic activity on the skin of a healthy subject;

and

monitoring the healthy subject's skin for inflammatory action.

24. (Original) The diagnostic method according to claim 23 wherein said feces is taken from an infant or a patient.

25. (Currently amended) A cloth of woven material to which is chemically associating ~~an inhibitor~~ the inhibitor of proteolytic activity of claim 1.

26. (Currently amended) A method to derive ~~protease inhibitors from plants or plant parts~~ the inhibitor of proteolytic activity of claim 1, comprising:

a) grinding the plant or plant parts to a pulp;

b) separating the solids from the pulp to provide a juice of the plant or plant part;

c) coagulating bulk proteins in said juice, preferably by acidifying and heating of the juice;

d) separating the coagulated proteins from the juice;

e) adjusting the pH to a value of the juice to about 4.0; and

- f) isolating the protease inhibitors from the juice by precipitating the protease inhibitors with sodium polyphosphate.